# A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat

> **NCT05320380** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Children's Oncology Group**

## Conditions studied

- Recurrent Acute Myeloid Leukemia
- Recurrent B Acute Lymphoblastic Leukemia
- Recurrent Mixed Phenotype Acute Leukemia
- Recurrent T Acute Lymphoblastic Leukemia
- Refractory Acute Myeloid Leukemia
- Refractory B Acute Lymphoblastic Leukemia
- Refractory Mixed Phenotype Acute Leukemia
- Refractory T Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Anti-CD123 ADC IMGN632
- **PROCEDURE:** Bone Marrow Aspiration and Biopsy
- **DRUG:** Cytarabine
- **DRUG:** Fludarabine Phosphate
- **DRUG:** Hydrocortisone Sodium Succinate
- **DRUG:** Liposome-encapsulated Daunorubicin-Cytarabine
- **DRUG:** Methotrexate
- **DRUG:** Prednisolone

## Key facts

- **NCT ID:** NCT05320380
- **Lead sponsor:** Children's Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-08-01
- **Primary completion:** 2023-09-01
- **Final completion:** 2023-09-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Withdrawn per CS0150757
- **Last updated:** 2023-09-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05320380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05320380, "A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT05320380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*